目的 探討坤泰膠囊聯(lián)合替勃龍治療圍絕經(jīng)期綜合征的臨床療效。方法 選取2019年10月-2021年3月合肥市第八人民醫(yī)院收治的80例圍絕經(jīng)期綜合征婦女作為研究對象，進行回顧性研究。根據(jù)治療方法將患者分為對照組和試驗組，每組40例。對照組患者均給予口服替勃龍治療，每次1.25 mg，每天1次；試驗組患者在對照組基礎上聯(lián)合口服坤泰膠囊治療，每次2.0 g，每天3次，兩組療程均為3個月。測定并記錄兩組患者治療前后的性激素水平及子宮內(nèi)膜厚度，采用改良Kupperman Index量表（KI）對兩組治療前后的臨床癥狀進行評分，以患者治療前后KI評分改善程度為依據(jù)評價兩組臨床治療效果，統(tǒng)計并比較兩組患者不良反應發(fā)生情況。結果 試驗組患者治療后的黃體生成素（LH）、促卵泡激素（FSH）水平均較治療前及對照組治療后明顯降低（P<0.05），雌二醇（E₂）水平均較治療前及對照組治療后明顯升高（P<0.05）；兩組患者治療前后及組間的子宮內(nèi)膜厚度差異均無統(tǒng)計學意義（P>0.05），但兩組治療后的KI評分均較治療前明顯降低（P<0.05）；試驗組患者臨床總有效率92.50%略高于對照組的87.50%，但差異無統(tǒng)計學意義（P>0.05）；試驗組患者臨床不良反應發(fā)生率7.50%明顯低于對照組的25.00%，差異具有統(tǒng)計學意義（P<0.05）。結論 在替勃龍治療基礎上加用坤泰膠囊，可有效改善圍絕經(jīng)期綜合征患者的臨床癥狀及性激素水平，減少不良反應的發(fā)生，其療效確切且用藥安全性高。

Objective To investigate the clinical efficacy of Kuntai Capsule combined with tibolone in the treatment of perimenopausal syndrome. Methods A retrospective study was conducted on 80 women with perimenopausal syndrome treated in Hefei Eighth People's Hospital from October 2019 to March 2021. According to the treatment methods, the patients were divided into control group and experimental group, with 40 cases in each group. The patients in the control group were treated with oral tibolone, 1.25 mg each time, once a day. On the basis of the control group, the patients in the experimental group were treated with Kuntai Capsule, 2.0 g each time, three times a day. The course of treatment of both groups was three months. The sex hormone levels and endometrial thickness of the two groups before and after treatment were measured and recorded. The clinical symptoms of the two groups before and after treatment were scored by the modified Kupperman Index (KI) scale. The clinical treatment effects of the two groups were evaluated based on the improvement of KI scores before and after treatment, and the adverse reactions of the two groups were counted and compared. Results The levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH) in the experimental group were significantly lower than those before treatment and the control group at the same period (P < 0.05), and the levels of estradiol（E₂）were significantly higher than those before treatment and the control group at the same period (P < 0.05). There was no significant difference in endometrial thickness between the two groups before and after treatment (P>0.05), but the KI score of the two groups after treatment was significantly lower than that before treatment (P < 0.05). The total clinical effective rate in the experimental group was 92.50%, which was slightly higher than 87.50% in the control group, but the difference was not statistically significant (P>0.05). The incidence of clinical adverse reactions in the experimental group was 7.50%, which was significantly lower than 25.00% in the control group (P < 0.05). Conclusion The use of Kuntai Capsule on the basis of tibolonetreatment can effectively improve the clinical symptoms and sex hormone level of patients with perimenopausal syndrome, reduce the occurrence of adverse reactions, have definite curative effect and high drug safety. Key words: Kuntai Capsule; perimenopausal syndrome; tibolone; luteinizing hormone; follicle stimulating hormone; estradiol

R984